The Effect of Early Life Aflatoxin Exposure on Growth, Immune

Total Page:16

File Type:pdf, Size:1020Kb

The Effect of Early Life Aflatoxin Exposure on Growth, Immune The effect of early life aflatoxin exposure on growth, immune function and cancer predisposition Jovita Marie Castelino Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds School of Medicine September 2013 I confirm that the work submitted is my own and that appropriate credit has been given where reference has been made to the work of others This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement © 2013 “The University of Leeds and Jovita Marie Castelino” Acknowledgements I am very grateful for the supervision, advice and support I received from my supervisors, Drs. Yun Yun Gong and Michael Routledge. I would also like to thank Professor Chris Wild and the International Agency for Research on Cancer for funding this research project. This work would not have been realised without collaboration with Shona Wilson and David Dunne from the Schistosomiasis Research Group, University of Cambridge; Branwen Hennig, Sophie Moore, Paula Dominguez-Salas, Andy Hall and Andrew Prentice from the London School of Hygiene and Tropical Medicine; and Zdenko Herceg and Hector Hernandez from the Epigenetics Group, IARC. I would also like to thank Marie Pierre Cros, Geoffroy Durand, Cyrille Cuenin, Ho- Sun Lee and Akram Ghantous for their advice and help with the whole genome work. Additionally, I would like to thank Yu-Kang Tu for his advice on the statistical analysis in Chapter 3. I am indebted to the contributions and invaluable advice from Hector Hernandez in the execution of the whole genome work and the preparation of the relevant sections in this thesis. Importantly, this work would not have been possible without the participants from Kenya and The Gambia. I would like to thank Anna Skromna, Victoria Richardson, Kay White, Anne Sutcliffe, Susan Shires, Catherine Whibley, André Nogueira Da Costa, Claire Smith, Qizhi Huang, John Huntriss, Angela Carter, Jill Callaghan, Chou Srey, Xiaoxi Pan, Nikoletta Pechlivani, Jon Askham, Bin Zhao, Jianping Lu, Matt Gage and Tim Noble, who have helped me during my time at LIGHT. I am very grateful and blessed to have had scientific and emotional support, advice and positive encouragement from my husband, Matthew Cotterill. I thank him for being with me every step of the way and allowing me to grow as a person. The emotional support and love from my wonderful parents, my beautiful and strong sisters, my ever-helpful in-laws and Mojo has also been vital throughout my PhD and I am forever indebted to them. iii Abstract Aflatoxin exposure through contamination of dietary staples is prevalent in developing regions such as sub-Saharan Africa. Aflatoxin exposure has been linked to a GT transversion in p53, which has been suggested to be the main mechanism of aflatoxin-associated liver carcinogenesis. In young children, in utero and weaning exposure has been linked to growth and immune function impairment through unknown mechanisms. The role of the insulin-like growth factor (IGF) axis was examined in aflatoxin-exposed Kenyan school-children. Through analysis of plasma samples, it was identified that 16% of the effect of aflatoxin on growth impairment was through disrupted IGF1 levels. It was also observed that mRNA and secreted protein levels of IGF growth-axis components were significantly reduced in aflatoxin-treated cultured liver cells. In another study using a Gambian mother-child cohort, it was determined that in most women aflatoxin exposure was consistently high or low during gestation and that this exposure was influenced by season of exposure. In infants born to highly aflatoxin-exposed women, significant changes to DNA methylation and gene expression patterns in white blood cells were observed in a number of genes following whole genome analysis. Among the observed changes, hypomethylation of HORMAD2 at the promoter-level and MIR24-2 at the gene-level as well as hypermethylation of CD3D at the promoter-level were identified and successfully validated by pyrosequencing. Additionally, USP4 and STAT3, associated with cancers and growth impairment, were both upregulated in the high AFB1 exposure group and were also successfully validated by qPCR. Changes in methylation and expression in aflatoxin-treated liver cells were assessed using a iv whole genome approach. Hypomethylation of IL2 and MIR24-2 at the gene level and upregulation of NFKB1A and IL6 were observed in AFB1-treated liver cells compared to controls. Overall, the study provides evidence that the IGF axis may be involved in aflatoxin-induced growth impairment and the STAT3 and NF-κB signalling pathways, associated with hepatocarcinogenesis and growth impairment, were found to be activated in both Gambian infants exposed in utero and in treated liver cells. These pathways may play important roles in the mechanisms of aflatoxin exposure-associated health effects and need to be explored further. v Table of Contents Acknowledgements ............................................................................................................... iii Abstract .................................................................................................................................. iv Table of Contents .................................................................................................................. vi List of Tables ......................................................................................................................... xi List of Figures ...................................................................................................................... xiv Abbreviations ...................................................................................................................... xvi 1 Introduction ..................................................................................................... 1 1.1 Literature Review ...................................................................................... 2 1.1.1 Discovery of Aflatoxins ............................................................................... 2 1.1.2 Contamination of crops with aflatoxin ......................................................... 4 1.1.3 Impact of aflatoxins on animal and human health ....................................... 6 1.1.3.1 Structure of AFB1 related to health effects .............................................. 6 1.1.3.2 Metabolism of AFB1 ................................................................................ 9 1.1.4 A brief history of the effects of AFB1 on the human liver ......................... 13 1.1.4.1 Evidence of a potential mechanism of AFB1-associated cancer ............ 15 1.1.4.2 Hepatitis B virus, aflatoxins and liver cancer ........................................ 17 1.1.5 Advantages of biomarkers ......................................................................... 18 1.1.6 Molecular markers of AFB1 exposure ........................................................ 19 1.1.6.1 Methods of AF-alb measurement ........................................................... 22 1.1.7 Aflatoxin exposure levels and associated health effects ............................ 24 1.1.7.1 AFB1 exposure and liver cancer risk ...................................................... 24 1.1.7.2 Epigenetics: Role in cancer prediction, diagnosis and prognosis .......... 30 1.1.7.3 Identifying mechanistic markers of gene expression and epigenetic alterations ............................................................................................................... 35 1.1.8 Child growth and development .................................................................. 38 1.1.9 AFB1 exposure and effects on growth ....................................................... 40 1.1.9.1 Mechanisms of growth impairment ....................................................... 44 1.1.9.2 Role of epigenetic modifications in growth ........................................... 50 1.1.10 The foetal origins of adult disease ............................................................. 51 1.2 Project Aims ............................................................................................ 56 2 Materials and Methods ................................................................................. 57 vi 2.1 AF-alb measurement ELISA ................................................................... 58 2.1.1 Modified AF-alb measurement ELISA ...................................................... 61 2.2 IGF1 and IGFBP3 ELISA measurement ................................................. 62 2.2.1 Plasma samples .......................................................................................... 62 2.2.2 Cell media samples .................................................................................... 63 2.3 Non-tumourigenic cell work .................................................................... 64 2.3.1 Cell maintenance ........................................................................................ 64 2.3.2 Cell cytotoxicity assay ............................................................................... 64 2.3.3 Cell treatment with AFB1 ........................................................................... 65 2.3.4 DNA extraction .......................................................................................... 66 2.3.5 RNA extraction .........................................................................................
Recommended publications
  • Immuno-Oncology Panel 1
    Immuno-Oncology panel 1 Gene Symbol Target protein name UniProt ID (& link) Modification* (56 analytes) ADA17 ADAM17 metalloprotease domain 17 P78536 *blanks mean the assay detects the ANXA1 Annexin A1 P04083 non-modified peptide sequence ANXA1 Annexin A1 P04083 ARG2 arginase, type II P78540 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS2996 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS367 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 C10orf54 / VISTA chromosome 10 open reading frame 54 Q9H7M9 CCL5 C-C motif chemokine ligand 5 P13501 CD14 CD14 molecule P08571 CD163 CD163 molecule Q86VB7 CD274 / PDL1 Programmed cell death 1 ligand 1 CD274 Q9NZQ7 CD33 CD33 molecule P20138 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD47 CD47 molecule Q08722 CD70 CD70 antigen P32970 CD74/HG2A CD74 molecule, major histocompatibility complex, class II invariant chain Q8SNA0 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 P31997 CX3CL1 C-X3-C motif chemokine ligand 1 P78423 CXCL10 C-X-C motif chemokine ligand 10 P02778 CXCL13 chemokine (C-X-C motif) ligand 13 O43927 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 Q86VV3 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 pY291 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 HAVCR2 hepatitis
    [Show full text]
  • Pan-Cancer Analysis Connects Tumor Matrisome to Immune Response
    www.nature.com/npjprecisiononcology ARTICLE OPEN Pan-cancer analysis connects tumor matrisome to immune response Su Bin Lim 1,2, Melvin Lee Kiang Chua 3,4,5, Joe Poh Sheng Yeong6,7, Swee Jin Tan8, Wan-Teck Lim7,9,10 and Chwee Teck Lim 1,2,11,12 Recent sequencing efforts unveil genomic landscapes of tumor microenvironment. A key compartment in this niche is the extracellular matrix (ECM) and its related components – matrisome. Yet, little is known about the extent to which matrisome pattern is conserved in progressive tumors across diverse cancer types. Using integrative genomic approaches, we conducted multi- platform assessment of a measure of deregulated matrisome associated with tumor progression, termed as tumor matrisome index (TMI), in over 30,000 patient-derived samples. Combined quantitative analyses of genomics and proteomics reveal that TMI is closely associated with mutational load, tumor pathology, and predicts survival across different malignancies. Interestingly, we observed an enrichment of specific tumor-infiltrating immune cell populations, along with signatures predictive of resistance to immune checkpoint blockade immunotherapy, and clinically targetable immune checkpoints in TMIhigh tumors. B7-H3 emerged as a particularly promising target for anti-tumor immunity in these tumors. Here, we show that matrisomal abnormalities could represent a potential clinically useful biomarker for prognostication and prediction of immunotherapy response. npj Precision Oncology (2019) 3:15 ; https://doi.org/10.1038/s41698-019-0087-0 INTRODUCTION Here we hypothesized that this specific pattern of deregulated The extracellular matrix (ECM) is a complex multi-spatial mesh- matrisome could be a common determinant of tumor aggression work of macromolecules with structural, biochemical and irrespective of tumor origin.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Transcriptome-Wide Profiling of the Neonatal Monocyte Response to E
    Transcriptome-wide profiling of the neonatal monocyte response to E. coli and S. epidermidis Emma de Jong, B.Sc. (Hons) This thesis is presented for the degree of Doctor of Philosophy School of Veterinary & Life Sciences 2015 Declaration I declare that this thesis is my own account of my research, and contains as its main content work that has not previously been submitted for a degree at any other tertiary education institution. .................................... (Emma de Jong) i ii Abstract Preterm infants are extremely vulnerable to life-threatening invasive infections (particularly with Staphylococcus epidermidis and Escherichia coli) however our understanding of their innate immune defences is limited. Furthermore, prenatal exposure to histologic chorioamnionitis (HCA) complicates 40–70% of preterm births and is known to modulate the risk for sepsis, yet the impact of HCA on the development of innate immunity is largely unknown. We hypothesised that inadequate monocyte activation by neonatal pathogens results in impaired innate immune responses thereby increasing preterm infants’ susceptibility to invasive infection, and that prenatal exposure to HCA overrides these impairments. Cell sorting and bacterial stimulation methodologies were developed and optimised specifically for working with human infant cord blood samples. RNA-sequencing was performed on purified cord blood monocytes from very preterm (≤31 weeks gestational age (GA)) and term infants (37–40 weeks GA) following challenge with live S. epidermidis or E. coli to identify gene/pathway differences specific to the preterm infant. Protein levels of inflammatory cytokines and chemokines were measured in paired monocyte culture supernatants. Preterm infants displayed a quantitative monocyte deficiency compared to term infants, manifesting as reduced frequencies of classical monocytes with significantly reduced CD14 expression.
    [Show full text]
  • Genome-Wide Association Study of Susceptibility to Idiopathic
    Edinburgh Research Explorer Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis Citation for published version: Allen, RJ, Guillen-Guio, B, Oldham, JM, Ma, S-F, Dressen, A, Paynton, ML, Kraven, LM, Obeidat, M, Li, X, Ng, M, Braybrooke, R, Molina-Molina, M, Hobbs, BD, Putman, RK, Sakornsakolpat, P, Booth, HL, Fahy, WA, Hart, SP, Hill, MR, Hirani, N, Hubbard, RB, McAnulty, RJ, Millar, AB, Navaratnam, V, Oballa, E, Parfrey, H, Saini, G, Whyte, MKB, Zhang, Y, Kaminski, N, Adegunsoye, A, Strek, ME, Neighbors, M, Sheng, XR, Gudmundsson, G, Gudnason, V, Hatabu, H, Lederer, DJ, Manichaikul, A, Newell, JD, O'Connor, GT, Ortega, VE, Xu, H, Fingerlin, TE, Bossé, Y, Hao, K, Joubert, P, Nickle, DC, Sin, DD, Timens, W, Furniss, D, Morris, AP, Zondervan, K, Hall, IP, Sayers, I, Tobin, MD, Maher, TM, Cho, MH, Hunninghake, GM, Schwartz, DA, Yaspan, BL, Molyneaux, PL, Flores, C, Noth, I, Jenkins, RG & Wain, LV 2019, 'Genome- Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis', American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201905-1017OC Digital Object Identifier (DOI): 10.1164/rccm.201905-1017OC Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: American Journal of Respiratory and Critical Care Medicine General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation.
    [Show full text]
  • Termination of RNA Polymerase II Transcription by the 5’-3’ Exonuclease Xrn2
    TERMINATION OF RNA POLYMERASE II TRANSCRIPTION BY THE 5’-3’ EXONUCLEASE XRN2 by MICHAEL ANDRES CORTAZAR OSORIO B.S., Universidad del Valle – Colombia, 2011 A thesis submitted to the Faculty of the Graduate School of the University of Colorado in partial fulfillment of the requirements for the degree of Doctor of Philosophy Molecular Biology Program 2018 This thesis for the Doctor of Philosophy degree by Michael Andrés Cortázar Osorio has been approved for the Molecular Biology Program by Mair Churchill, Chair Richard Davis Jay Hesselberth Thomas Blumenthal James Goodrich David Bentley, Advisor Date: Aug 17, 2018 ii Cortázar Osorio, Michael Andrés (Ph.D., Molecular Biology) Termination of RNA polymerase II transcription by the 5’-3’ exonuclease Xrn2 Thesis directed by Professor David L. Bentley ABSTRACT Termination of transcription occurs when RNA polymerase (pol) II dissociates from the DNA template and releases a newly-made mRNA molecule. Interestingly, an active debate fueled by conflicting reports over the last three decades is still open on which of the two main models of termination of RNA polymerase II transcription does in fact operate at 3’ ends of genes. The torpedo model indicates that the 5’-3’ exonuclease Xrn2 targets the nascent transcript for degradation after cleavage at the polyA site and chases pol II for termination. In contrast, the allosteric model asserts that transcription through the polyA signal induces a conformational change of the elongation complex and converts it into a termination-competent complex. In this thesis, I propose a unified allosteric-torpedo mechanism. Consistent with a polyA site-dependent conformational change of the elongation complex, I found that pol II transitions at the polyA site into a mode of slow transcription elongation that is accompanied by loss of Spt5 phosphorylation in the elongation complex.
    [Show full text]
  • Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders
    177 Arch Neuropsychitry 2020;57:177−191 RESEARCH ARTICLE https://doi.org/10.29399/npa.24890 Chromosomal Microarray Analysis in Turkish Patients with Unexplained Developmental Delay and Intellectual Developmental Disorders Hakan GÜRKAN1 , Emine İkbal ATLI1 , Engin ATLI1 , Leyla BOZATLI2 , Mengühan ARAZ ALTAY2 , Sinem YALÇINTEPE1 , Yasemin ÖZEN1 , Damla EKER1 , Çisem AKURUT1 , Selma DEMİR1 , Işık GÖRKER2 1Faculty of Medicine, Department of Medical Genetics, Edirne, Trakya University, Edirne, Turkey 2Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey ABSTRACT Introduction: Aneuploids, copy number variations (CNVs), and single in 39 (39/123=31.7%) patients. Twelve CNV variant of unknown nucleotide variants in specific genes are the main genetic causes of significance (VUS) (9.75%) patients and 7 CNV benign (5.69%) patients developmental delay (DD) and intellectual disability disorder (IDD). were reported. In 6 patients, one or more pathogenic CNVs were These genetic changes can be detected using chromosome analysis, determined. Therefore, the diagnostic efficiency of CMA was found to chromosomal microarray (CMA), and next-generation DNA sequencing be 31.7% (39/123). techniques. Therefore; In this study, we aimed to investigate the Conclusion: Today, genetic analysis is still not part of the routine in the importance of CMA in determining the genomic etiology of unexplained evaluation of IDD patients who present to psychiatry clinics. A genetic DD and IDD in 123 patients. diagnosis from CMA can eliminate genetic question marks and thus Method: For 123 patients, chromosome analysis, DNA fragment analysis alter the clinical management of patients. Approximately one-third and microarray were performed. Conventional G-band karyotype of the positive CMA findings are clinically intervenable.
    [Show full text]
  • Genome-Wide DNA Methylation in Chronic Myeloid Leukaemia
    Genome-wide DNA Methylation in Chronic Myeloid Leukaemia Alexandra Bazeos Imperial College London Department of Medicine Centre for Haematology Thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy of Imperial College London 2015 1 Abstract Epigenetic alterations occur frequently in leukaemia and might account for differences in clinical phenotype and response to treatment. Despite the consistent presence of the BCR-ABL1 fusion gene in Philadelphia-positive chronic myeloid leukaemia (CML), the clinical course of patients treated with tyrosine kinase inhibitors (TKI) is heterogeneous. This might be due to differing DNA methylation profiles between patients. Therefore, a validated, epigenome-wide survey in CML CD34+ progenitor cells was performed in newly diagnosed chronic phase patients using array-based DNA methylation and gene expression profiling. In practice, the CML DNA methylation signature was remarkably homogeneous; it differed from CD34+ cells of normal persons and did not correlate with an individual patient’s response to TKI therapy. Using a meta-analysis tool it was possible to demonstrate that this signature was highly enriched for developmentally dynamic regions of the human methylome and represents a combination of CML-unique, myeloid leukemia- specific and pan-cancer sub-signatures. The CML profile involved aberrantly methylated genes in signaling pathways already implicated in CML leukaemogenesis, including TGF-beta, Wnt, Jak-STAT and MAPK. Furthermore, a core set of differentially methylated promoters were identified that likely have a role in modulating gene expression levels. In conclusion, the findings are consistent with the notion that CML starts with the acquisition of a BCR-ABL1 fusion gene by a haematopoietic stem cell, which then either causes or cooperates with a series of DNA methylation changes that are specific for CML.
    [Show full text]
  • Triangulating Molecular Evidence to Prioritise Candidate Causal Genes at Established Atopic Dermatitis Loci
    medRxiv preprint doi: https://doi.org/10.1101/2020.11.30.20240838; this version posted November 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Triangulating molecular evidence to prioritise candidate causal genes at established atopic dermatitis loci Maria K Sobczyk1, Tom G Richardson1, Verena Zuber2,3, Josine L Min1, eQTLGen Consortium4, BIOS Consortium5, GoDMC, Tom R Gaunt1, Lavinia Paternoster1* 1) MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK 2) Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK 3) MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK 4) Members of the eQTLGen Consortium are listed in: Supplementary_Consortium_members.docx 5) Members of the BIOS Consortium are listed in: Supplementary_Consortium_members.docx Abstract Background: Genome-wide association studies for atopic dermatitis (AD, eczema) have identified 25 reproducible loci associated in populations of European descent. We attempt to prioritise candidate causal genes at these loci using a multifaceted bioinformatic approach and extensive molecular resources compiled into a novel pipeline: ADGAPP (Atopic Dermatitis GWAS Annotation & Prioritisation Pipeline). Methods: We identified a comprehensive list of 103 accessible
    [Show full text]
  • The Human Gene Connectome As a Map of Short Cuts for Morbid Allele Discovery
    The human gene connectome as a map of short cuts for morbid allele discovery Yuval Itana,1, Shen-Ying Zhanga,b, Guillaume Vogta,b, Avinash Abhyankara, Melina Hermana, Patrick Nitschkec, Dror Friedd, Lluis Quintana-Murcie, Laurent Abela,b, and Jean-Laurent Casanovaa,b,f aSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; bLaboratory of Human Genetics of Infectious Diseases, Necker Branch, Paris Descartes University, Institut National de la Santé et de la Recherche Médicale U980, Necker Medical School, 75015 Paris, France; cPlateforme Bioinformatique, Université Paris Descartes, 75116 Paris, France; dDepartment of Computer Science, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel; eUnit of Human Evolutionary Genetics, Centre National de la Recherche Scientifique, Unité de Recherche Associée 3012, Institut Pasteur, F-75015 Paris, France; and fPediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, 75015 Paris, France Edited* by Bruce Beutler, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 15, 2013 (received for review October 19, 2012) High-throughput genomic data reveal thousands of gene variants to detect a single mutated gene, with the other polymorphic genes per patient, and it is often difficult to determine which of these being of less interest. This goes some way to explaining why, variants underlies disease in a given individual. However, at the despite the abundance of NGS data, the discovery of disease- population level, there may be some degree of phenotypic homo- causing alleles from such data remains somewhat limited. geneity, with alterations of specific physiological pathways under- We developed the human gene connectome (HGC) to over- come this problem.
    [Show full text]
  • Exploration of the Relationships Between Tumor Mutation Burden with Immune Infiltrates in Clear Cell Renal Cell Carcinoma
    648 Original Article Page 1 of 16 Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma Chuanjie Zhang1#, Zongtai Li2#, Feng Qi3#, Xin Hu4, Jun Luo5 1Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2Department of Medical Oncology, Gaozhou People’s Hospital, Gaozhou 525200, China; 3Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; 4First Clinical Medical College of Nanjing Medical University, Nanjing 210029, China; 5Department of Urology, Shanghai Fourth People’s Hospital affiliated to Tongji University School of Medicine, Shanghai 200081, China Contributions: (I) Conception and design: J Luo, C Zhang; (II) Administrative support: C Zhang; (III) Provision of study materials or patients: Z Li, F Qi; (IV) Collection and assembly of data: X Hu; (V) Data analysis and interpretation: J Luo, C Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this article. Correspondence to: Jun Luo. Department of Urology, Shanghai Fourth People’s Hospital affiliated to Tongji University School of Medicine, No. 1878 North Sichuan Road, Hongkou District, Shanghai 200081, China. Email: [email protected]. Background: Whether tumor mutation burden (TMB) correlated with improved survival outcomes or promotion of immunotherapies remained controversy in various malignancies. We aimed to investigate the prognosis of TMB and the potential association with immune infiltrates in clear cell renal cell carcinoma (ccRCC). Methods: We downloaded the somatic mutation data of 336 ccRCC patients from the Cancer Genome Atlas (TCGA) database, and analyzed the mutation profiles with “maftools” package.
    [Show full text]
  • Human Social Genomics in the Multi-Ethnic Study of Atherosclerosis
    Getting “Under the Skin”: Human Social Genomics in the Multi-Ethnic Study of Atherosclerosis by Kristen Monét Brown A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Epidemiological Science) in the University of Michigan 2017 Doctoral Committee: Professor Ana V. Diez-Roux, Co-Chair, Drexel University Professor Sharon R. Kardia, Co-Chair Professor Bhramar Mukherjee Assistant Professor Belinda Needham Assistant Professor Jennifer A. Smith © Kristen Monét Brown, 2017 [email protected] ORCID iD: 0000-0002-9955-0568 Dedication I dedicate this dissertation to my grandmother, Gertrude Delores Hampton. Nanny, no one wanted to see me become “Dr. Brown” more than you. I know that you are standing over the bannister of heaven smiling and beaming with pride. I love you more than my words could ever fully express. ii Acknowledgements First, I give honor to God, who is the head of my life. Truly, without Him, none of this would be possible. Countless times throughout this doctoral journey I have relied my favorite scripture, “And we know that all things work together for good, to them that love God, to them who are called according to His purpose (Romans 8:28).” Secondly, I acknowledge my parents, James and Marilyn Brown. From an early age, you two instilled in me the value of education and have been my biggest cheerleaders throughout my entire life. I thank you for your unconditional love, encouragement, sacrifices, and support. I would not be here today without you. I truly thank God that out of the all of the people in the world that He could have chosen to be my parents, that He chose the two of you.
    [Show full text]